Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort study

Partha Basu, Richard Muwonge, Neerja Bhatla, Bhagwan M Nene, Smita Joshi, Pulikottil O Esmy, Usha Rani Reddy Poli, Geeta Joshi, Yogesh Verma, Eric Zomawia, Surendra S Shastri, Sharmila Pimple, Devasena Anantharaman, Priya R Prabhu, Sanjay Hingmire, Catherine Sauvaget, Eric Lucas, Michael Pawlita, Tarik Gheit, Kasturi Jayant, Sylla G Malvi, Maqsood Siddiqi, Angelika Michel, Julia Butt, Subha Sankaran, Thiraviam Pillai Rameshwari Ammal Kannan, Rintu Varghese, Uma Divate, Martina Willhauck-Fleckenstein, Tim Waterboer, Martin Müller, Peter Sehr, Shachi Vashist, Gauravi Mishra, Radhika Jadhav, Ranjit Thorat, Massimo Tommasino, M Radhakrishna Pillai, Rengaswamy Sankaranarayanan, Indian HPV vaccine study group, Partha Basu, Richard Muwonge, Neerja Bhatla, Bhagwan M Nene, Smita Joshi, Pulikottil O Esmy, Usha Rani Reddy Poli, Geeta Joshi, Yogesh Verma, Eric Zomawia, Surendra S Shastri, Sharmila Pimple, Devasena Anantharaman, Priya R Prabhu, Sanjay Hingmire, Catherine Sauvaget, Eric Lucas, Michael Pawlita, Tarik Gheit, Kasturi Jayant, Sylla G Malvi, Maqsood Siddiqi, Angelika Michel, Julia Butt, Subha Sankaran, Thiraviam Pillai Rameshwari Ammal Kannan, Rintu Varghese, Uma Divate, Martina Willhauck-Fleckenstein, Tim Waterboer, Martin Müller, Peter Sehr, Shachi Vashist, Gauravi Mishra, Radhika Jadhav, Ranjit Thorat, Massimo Tommasino, M Radhakrishna Pillai, Rengaswamy Sankaranarayanan, Indian HPV vaccine study group

Abstract

Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15-18 years of age (Bhatla et al., 2018) [7]. The number of participants recruited at 15-18 years of age was 1515 and 1795 in the 3-dose and the 2-dose groups respectively. At a median follow-up of 7 years, incident HPV 16/18 infections were detected in 1.6% women receiving two doses and 0.8% women receiving three doses at 15-18 years. Frequency of incident infection was 7.0% in the age- and site-matched unvaccinated women (N = 1484). No persistent infection from HPV 16 was observed in the 2- or 3-dose recipients and one (0.2%) persistent HPV 18 infection was documented, each in the 3-dose and 2-dose cohorts. Among the unvaccinated women, the frequency of HPV 16/18 persistent infection was 1.7%. The protection offered by two doses of quadrivalent HPV vaccine against incident and persistent infections in recipients at 15-18 years is comparable to that seen in 3-dose recipients at 15-18 years.

Keywords: Age 15–18 years; Human papillomavirus; Immunogenicity; Incident infections; Persistent infections; Quadrivalent vaccine; Two doses.

Copyright © 2019. Published by Elsevier B.V.

References

    1. World Health Organization . Weekly Epidemiology Record. 2014. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – conclusions and recommendations; pp. 221–236.
    1. World Health Organization, Primary end-points for prophylactic HPV vaccine trials. IARC Working Group Report, Volume 7, IARC, Lyon, 2014.
    1. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. J. Am. Med. Assoc. 2013;309:1793–1802.
    1. D’Addario M., Scott P., Redmond S., Low N. Institute of Social and Preventive Medicine (ISPM), University of Bern; Bern, Switzerland: 2014. HPV Vaccines: Systematic Review of Literature on Alternative Vaccination Schedules. (Report on a two doses vs. three doses schedule, 3rd March 2014)
    1. World Health Organization. Immunization in a Changing World leadership, population growth, migration, emerging diseases, polio transition. IVB Director’s report to SAGE − 17 April 2018. Available from: (accessed on 8 November 2018).
    1. World Health Organization . Weekly Epidemiology Record. 2017. Human Papillomavirus Vaccine: WHO Position Paper; pp. 241–298.
    1. Bhatla N., Nene B.M., Joshi S., Esmy P.O., Poli U.R.R., Joshi G G. Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India. Papillomavirus Res. 2018;5:163–171.
    1. Sankaranarayanan R., Prabhu P.R., Pawlita M., Gheit T., Bhatla N., Muwonge R. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17:67–77.
    1. Sankaranarayanan R., Joshi S., Muwonge R., Esmy P.O., Basu P., Prabhu P. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36:4783–4791.
    1. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum. Vacc. 2011;7:1374–1386.
    1. Lazcano-Ponce E., Stanley M., Muñoz N., Torres L., Cruz-Valdez A., Salmerón J. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32:725–732.
    1. Sow P.S., Watson-Jones D., Kiviat N., Changalucha J., Mbaye K.D., Brown J J. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. J. Infect. Dis. 2013;207:1753–1763.
    1. Esposito S., Birlutiu V., Jarcuska P., Perino A., Man S.C., Vladareanu R. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr. Infect. Dis. J. 2011;30:e49–e55.
    1. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J. Natl. Cancer Inst. 2011;103:1444–1451.
    1. Puerto D., Reyes V., Lozano C., Buitrago L., Garcia D., Murillo R.H. Detection and genotyping of HPV DNA in a group of unvaccinated young women from Colombia: baseline measures prior to future monitoring program. Cancer Prev. Res. 2018;11:581–592.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe